A new formulated anti-cancer drug, NDAT in combination with first anti-cancer drugs such as cetuximabgefitinib has been shown to enhance anti-cancer growth activities of cetuximabgefitinib in colorectal cancer cells that are resistant to those first line anti-cancer drugs. The potentiating effect of NDAT on cetuximabgefitinib is even better than that in cell cultures because NDAT ca

"Our product is multi-functional drug with less cytotoxicity which has been demonstrated in xenograft studies.  

"Our product can overcomereduce the drug-resistance usually happening in patients with mutant oncogenesother unknown characters. It can be used in patients with late stage colorectal cancerother types of cancer which are unable to be surgically removedare not responding to chemotherapy.